Inicio>>Signaling Pathways>> Immunology/Inflammation>> NF-κB>>Tomatidine (hydrochloride)

Tomatidine (hydrochloride)

Catalog No.GC45064

La tomatidina (clorhidrato) actúa como un agente antiinflamatorio al bloquear la señalización de NF-κB y JNK.

Products are for research use only. Not for human use. We do not sell to patients.

Tomatidine (hydrochloride) Chemical Structure

Cas No.: 6192-62-7

Tamaño Precio Disponibilidad Cantidad
10mg
46,00 $
Disponible
25mg
88,00 $
Disponible
50mg
163,00 $
Disponible
100mg
303,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tomatidine is a steroidal alkaloid that has been found in the skins and leaves of tomatoes. It suppresses NF-κB signaling in LPS-stimulated macrophages, blocking induced expression of inducible nitric oxide synthase (iNOS) and COX-2. Tomatidine inhibits acid sphingomyelinase activity by 84.2% when used at a concentration of 10 mM. It also has antibacterial properties, preferentially blocking the replication of S. aureus variants that are pathogenic in cystic fibrosis over normal strains (MICs = 0.12 and >16 µg/ml, respectively). It prevents skeletal muscle atrophy associated with fasting or spinal cord injury in mice. Tomatidine has also been used as a negative control for cyclopamine in studies involving signaling mediated by the hedgehog pathway.

Reseñas

Review for Tomatidine (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tomatidine (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.